131 related articles for article (PubMed ID: 38522775)
21. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model.
Ren X; Corrigan DT; Zang X
STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885
[TBL] [Abstract][Full Text] [Related]
22. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
[TBL] [Abstract][Full Text] [Related]
24. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
25. Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma.
Zhang MJ; Wang S; Wu CC; Wu L; Sun ZJ
J Oral Pathol Med; 2022 Apr; 51(4):379-387. PubMed ID: 35226778
[TBL] [Abstract][Full Text] [Related]
26. Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases.
Achinko DA; Dormer A; Narayanan M; Norman EF
BMC Immunol; 2021 Jul; 22(1):49. PubMed ID: 34320928
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
28. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
Front Immunol; 2020; 11():681. PubMed ID: 32477326
[TBL] [Abstract][Full Text] [Related]
29. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
30. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
Janakiram M; Chinai JM; Zhao A; Sparano JA; Zang X
Oncoimmunology; 2015 Aug; 4(8):e1026534. PubMed ID: 26405587
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment.
Luo M; Lin Y; Liang R; Li Y; Ge L
J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677
[TBL] [Abstract][Full Text] [Related]
32. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.
Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S
Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123
[TBL] [Abstract][Full Text] [Related]
33. Comparison of mismatch repair and immune checkpoint protein profile with histopathological parameters in pancreatic, periampullary/ampullary, and choledochal adenocarcinomas.
Aydın AH; Turhan N
World J Gastrointest Oncol; 2024 Mar; 16(3):875-882. PubMed ID: 38577456
[TBL] [Abstract][Full Text] [Related]
34. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
Wei L; Tang L; Chang H; Huo S; Li Y
Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
[TBL] [Abstract][Full Text] [Related]
35. The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma.
Byun JM; Cho HJ; Park HY; Lee DS; Choi IH; Kim YN; Jeong CH; Kim DH; Hwa Im D; Min BJ; Lee KB; Sung MS; Jeong DH
Medicine (Baltimore); 2021 Jan; 100(1):e23691. PubMed ID: 33429737
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
Wang B; Ran Z; Liu M; Ou Y
Front Immunol; 2019; 10():1573. PubMed ID: 31379814
[TBL] [Abstract][Full Text] [Related]
37. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
Long L; Zhang L; Yang Y; Zhou Y; Chen H
Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
[No Abstract] [Full Text] [Related]
38. Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
Nishihara D; Kijima T; Arai K; Kamai T
Int Urol Nephrol; 2023 Apr; 55(4):867-874. PubMed ID: 36598731
[TBL] [Abstract][Full Text] [Related]
39. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R
Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of HHLA2 as a Novel Therapeutic Target for Colorectal Cancer.
Wang H; An Z; Liu Y; Ding G; Deng G; Ji C; Gong Y
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38299402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
